SNTB2

Across TCGA pan-cancer cohorts, SNTB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SNTB2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SNTB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SNTB2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where SNTB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.861	0.276	.018	27	view →
PDAC	OS	Quartile	II,III,IV	0.641	0.338	.001	19	view →
LUAD	DFS	Quartile	III,IV	0.372	0.953	.006	6	view →
HNSC	OS	Median	All	0.633	0.778	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SNTB2–CCRCC (DFS)

Open the CCRCC breakdown →